La Jolla Pharmaceutical Co (LJPC)

[starbuxsux]

$LJPC La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2019

GlobeNewswire GlobeNewswire•March 2, 2020

For the three months ended December 31, 2019, GIAPREZA U.S. net sales were $7.3 million, up 74% from the three months ended December 31, 2018 and up 28% from the three months ended September 30, 2019. Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. GIAPREZA U.S. net sales were $23.1 million in 2019 compared to $10.1 million in 2018, an increase of 129%. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.

La Jolla’s net loss for the three and twelve months ended December 31, 2019 was $25.2 million and $116.5 million, or $0.93 per share and $4.30 per share, respectively, compared to $45.4 million and $199.5 million, or $1.73 per share and $7.85 per share, respectively, for the same periods in 2018.

As of December 31, 2019, La Jolla had $87.8 million in cash, compared to $172.6 million as of December 31, 2018. Net cash used in operating activities for the three and twelve months ended December 31, 2019 was $17.1 million and $85.0 million, respectively, compared to $32.0 million and $152.4 million, respectively, for the same periods in 2018. La Jolla has no debt.

https://finance.yahoo.com/news/la-jolla-pharmaceutical-company-announces-133010981.html